285 related articles for article (PubMed ID: 24582269)
21. Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors.
Kotteas EA; Charpidou AG; Syrigos KN
Anticancer Drugs; 2010 Feb; 21(2):151-68. PubMed ID: 20016368
[TBL] [Abstract][Full Text] [Related]
22. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
24. Third-line therapy in advanced non-small cell lung cancer.
Ying Geng Z; Chang Jiao S; Cui Liu S; Li Y; Feng Liu Z; Qing Zhang G; Jie Wang L; Qu F
J BUON; 2013; 18(4):899-907. PubMed ID: 24344015
[TBL] [Abstract][Full Text] [Related]
25. Molecularly targeted therapies in locally advanced non-small-cell lung cancer.
Devarakonda S; Morgensztern D; Govindan R
Clin Lung Cancer; 2013 Sep; 14(5):467-72. PubMed ID: 23684057
[TBL] [Abstract][Full Text] [Related]
26. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
27. Novel targeted therapies for non-small cell lung cancer.
Smith PW; Denlinger CE; Jones DR
Thorac Surg Clin; 2006 Nov; 16(4):353-66. PubMed ID: 17240823
[TBL] [Abstract][Full Text] [Related]
28. Current treatments for advanced stage non-small cell lung cancer.
Stinchcombe TE; Socinski MA
Proc Am Thorac Soc; 2009 Apr; 6(2):233-41. PubMed ID: 19349493
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives.
Pakkala S; Ramalingam SS
Curr Opin Oncol; 2016 Mar; 28(2):150-8. PubMed ID: 26809014
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?
Wozniak AJ; Gadgeel SM
Oncology (Williston Park); 2007 Feb; 21(2):163-71; discussion 171, 174, 179-82. PubMed ID: 17396481
[TBL] [Abstract][Full Text] [Related]
31. Erlotinib in non-small cell lung cancer treatment: current status and future development.
Gridelli C; Bareschino MA; Schettino C; Rossi A; Maione P; Ciardiello F
Oncologist; 2007 Jul; 12(7):840-9. PubMed ID: 17673615
[TBL] [Abstract][Full Text] [Related]
32. Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Herbst RS; Bunn PA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5813-24. PubMed ID: 14676101
[TBL] [Abstract][Full Text] [Related]
33. Axitinib for the treatment of advanced non-small-cell lung cancer.
King JW; Lee SM
Expert Opin Investig Drugs; 2013 Jun; 22(6):765-73. PubMed ID: 23452008
[TBL] [Abstract][Full Text] [Related]
34. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Langer CJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapies and non-small-cell lung cancer: new developments.
Gridelli C
Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
[No Abstract] [Full Text] [Related]
36. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
Gridelli C; Maione P; Rossi A; De Marinis F
Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
[TBL] [Abstract][Full Text] [Related]
37. Preoperative chemoradiotherapy using cisplatin plus S-1 can induce downstaging in patients with locally advanced (stage III) non-small-cell lung cancer.
Kato M; Onishi H; Matsumoto K; Tsuruta N; Higuchi K; Motoshita J; Katano M
Anticancer Res; 2012 Nov; 32(11):5099-104. PubMed ID: 23155287
[TBL] [Abstract][Full Text] [Related]
38. First-line treatment for advanced non-small-cell lung cancer.
Laskin JJ; Sandler AB
Oncology (Williston Park); 2005 Nov; 19(13):1671-6; discussion 1678-80. PubMed ID: 16425521
[TBL] [Abstract][Full Text] [Related]
39. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
Langer CJ; Mok T; Postmus PE
Cancer Treat Rev; 2013 May; 39(3):252-60. PubMed ID: 22703830
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
